EBS News and Press, Emergent Biosolutions Inc. From 11/01/18

Emergent BioSolutions Inc. (EBS) Q3 2018 Results Conference Call November 01, 2018 05:00 PM ET Executives Bob Burrows - Vice President of Investor Relations Dan Abdun Nabi - Chief Executive Officer Bob Kramer - President and Chief Operating Officer Rich Lindahl - Chief Financia...

Emergent BioSolutions (NYSE: EBS ): Q3 Non-GAAP EPS of $0.55 misses by $0.03 ; GAAP EPS of $0.41 misses by $0.14 . More news on: Emergent BioSolutions Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Q3 2018 performance in line with guidance Revises full year 2018 financial forecast to reflect anticipated strong full year organic business performance, expected at the higher end of the previous forecast, and impact of PaxVax and Adapt Pharma acquisitions GAITHERSBURG, Md., Nov. 01, ...

AAPL , ACIA , ACLS , AIRG , AIV , ALEX , AMH , ANET , AOSL , APPN , ARCB , ATGE , ATHN , ATR , ATRC , ATSG , BCOV , BFAM , BIO , BL , BLDR , BNFT , BRKR , BVX , CARB , CATM , CBPO , CBS , CC , CCRN , CECO , CERS , CHEF , CNMD , CNXN , CORT , CPS , CPSI ...

NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of StoneMor Partners L.P. (NYSE:STON), Catalyst Biosciences, Inc. (NASDAQ:CB...

New initiatives make free doses and educational materials available to thousands of public libraries & YMCAs in the U.S. GAITHERSBURG, Md., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced, through its subsidiary Adapt Pharma, the launch ...

The FDA announces a two-day advisory committee, to be held in December, to solicit input and advice on ways to increase access to opioid overdose medication naloxone. More news on: Emergent BioSolutions Inc., Adamis Pharmaceuticals Corp., Opiant Pharmaceuticals, Inc., Healthcare stocks n...

Value investing is not just about buying stocks with low valuation metrics, that's a too simplistic and myopic approach. The true essence of value investing is buying a company for a market price below the intrinsic value of the business. All else the same, a business with superior growth ra...

GAITHERSBURG, Md., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of Adapt Pharma and its flagship product NARCAN ® (naloxone HCl) Nasal Spray, the first and only intranasal form of naloxone approved by the...

GAITHERSBURG, Md., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 1, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2018, recent business developments, revenue guidance for ...